...
search icon
arwr-img

Arrowhead Pharmaceuticals Inc, Common Stock

ARWR

NSQ

$11.24

-$0.11

(-0.97%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.69B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
2.38M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.00
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$9.57 L
$30.41 H
$11.24

About Arrowhead Pharmaceuticals Inc, Common Stock

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameARWRSectorS&P500
1-Week Return1.17%1.04%0.24%
1-Month Return-27.95%-7.14%-7.32%
3-Month Return-42.54%-2.78%-12.05%
6-Month Return-46.07%-10.56%-9.73%
1-Year Return-50.11%-1.55%5.05%
3-Year Return-74.64%-0.6%20.03%
5-Year Return-69.25%35.24%83.31%
10-Year Return58.76%85.96%153.54%

Financials

Sep '20Sep '21Sep '22Sep '23Sep '245YR TREND
Total Revenue87.99M138.29M243.23M240.74M3.55M[{"date":"2020-09-30","value":36.18,"profit":true},{"date":"2021-09-30","value":56.85,"profit":true},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":98.97,"profit":true},{"date":"2024-09-30","value":1.46,"profit":true}]
Cost of Revenue--10.42M12.49M-[{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":83.41,"profit":true},{"date":"2023-09-30","value":100,"profit":true},{"date":"2024-09-30","value":"-","profit":true}]
Gross Profit87.99M138.29M243.23M240.74M3.55M[{"date":"2020-09-30","value":36.18,"profit":true},{"date":"2021-09-30","value":56.85,"profit":true},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":98.97,"profit":true},{"date":"2024-09-30","value":1.46,"profit":true}]
Gross Margin100.00%100.00%100.00%100.00%100.00%[{"date":"2020-09-30","value":100,"profit":true},{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":100,"profit":true},{"date":"2024-09-30","value":100,"profit":true}]
Operating Expenses181.15M287.32M421.74M445.74M604.63M[{"date":"2020-09-30","value":29.96,"profit":true},{"date":"2021-09-30","value":47.52,"profit":true},{"date":"2022-09-30","value":69.75,"profit":true},{"date":"2023-09-30","value":73.72,"profit":true},{"date":"2024-09-30","value":100,"profit":true}]
Operating Income(93.16M)(149.04M)(178.51M)(205.00M)(601.08M)[{"date":"2020-09-30","value":-9315880300,"profit":false},{"date":"2021-09-30","value":-14903600000,"profit":false},{"date":"2022-09-30","value":-17850700000,"profit":false},{"date":"2023-09-30","value":-20500200000,"profit":false},{"date":"2024-09-30","value":-60108000000,"profit":false}]
Total Non-Operating Income/Expense17.80M14.31M10.83M(4.52M)(21.01M)[{"date":"2020-09-30","value":100,"profit":true},{"date":"2021-09-30","value":80.4,"profit":true},{"date":"2022-09-30","value":60.85,"profit":true},{"date":"2023-09-30","value":-25.37,"profit":false},{"date":"2024-09-30","value":-118.05,"profit":false}]
Pre-Tax Income(84.55M)(140.85M)(172.71M)(206.49M)(612.46M)[{"date":"2020-09-30","value":-8455082600,"profit":false},{"date":"2021-09-30","value":-14084600000,"profit":false},{"date":"2022-09-30","value":-17270900000,"profit":false},{"date":"2023-09-30","value":-20649100000,"profit":false},{"date":"2024-09-30","value":-61246000000,"profit":false}]
Income Taxes2.40K2.00K3.79M2.78M(2.77M)[{"date":"2020-09-30","value":0.06,"profit":true},{"date":"2021-09-30","value":0.05,"profit":true},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":73.55,"profit":true},{"date":"2024-09-30","value":-73.1,"profit":false}]
Income After Taxes(84.55M)(140.85M)(176.49M)(209.28M)(609.69M)[{"date":"2020-09-30","value":-8455322600,"profit":false},{"date":"2021-09-30","value":-14084800000,"profit":false},{"date":"2022-09-30","value":-17649400000,"profit":false},{"date":"2023-09-30","value":-20927500000,"profit":false},{"date":"2024-09-30","value":-60969300000,"profit":false}]
Income From Continuous Operations(84.55M)(140.85M)(172.71M)(209.28M)(609.69M)[{"date":"2020-09-30","value":-8455322600,"profit":false},{"date":"2021-09-30","value":-14084800000,"profit":false},{"date":"2022-09-30","value":-17270900000,"profit":false},{"date":"2023-09-30","value":-20927500000,"profit":false},{"date":"2024-09-30","value":-60969300000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true}]
Net Income(84.55M)(140.85M)(176.49M)(205.28M)(599.49M)[{"date":"2020-09-30","value":-8455322600,"profit":false},{"date":"2021-09-30","value":-14084800000,"profit":false},{"date":"2022-09-30","value":-17649400000,"profit":false},{"date":"2023-09-30","value":-20527500000,"profit":false},{"date":"2024-09-30","value":-59949300000,"profit":false}]
EPS (Diluted)(0.84)(1.36)(1.68)(1.92)(5.01)[{"date":"2020-09-30","value":-84,"profit":false},{"date":"2021-09-30","value":-136,"profit":false},{"date":"2022-09-30","value":-168,"profit":false},{"date":"2023-09-30","value":-192,"profit":false},{"date":"2024-09-30","value":-501,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ARWR
Cash Ratio 5.90
Current Ratio 6.09

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ARWR
ROA (LTM) -47.71%
ROE (LTM) -565.33%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ARWR
Debt Ratio Lower is generally better. Negative is bad. 0.94
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.05

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ARWR
Trailing PE NM
Forward PE 111.11
P/S (TTM) 623.42
P/B 29.64
Price/FCF NM
EV/R 612.35
EV/Ebitda NM
PEG NM

FAQs

What is Arrowhead Pharmaceuticals Inc share price today?

Arrowhead Pharmaceuticals Inc (ARWR) share price today is $11.24

Can Indians buy Arrowhead Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Arrowhead Pharmaceuticals Inc (ARWR) on Vested. To buy Arrowhead Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ARWR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Arrowhead Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Arrowhead Pharmaceuticals Inc (ARWR) via the Vested app. You can start investing in Arrowhead Pharmaceuticals Inc (ARWR) with a minimum investment of $1.

How to invest in Arrowhead Pharmaceuticals Inc shares from India?

You can invest in shares of Arrowhead Pharmaceuticals Inc (ARWR) via Vested in three simple steps:

  • Click on Sign Up or Invest in ARWR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Arrowhead Pharmaceuticals Inc shares
What is Arrowhead Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Arrowhead Pharmaceuticals Inc (ARWR) is $30.41. The 52-week low price of Arrowhead Pharmaceuticals Inc (ARWR) is $9.57.

What is Arrowhead Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Arrowhead Pharmaceuticals Inc (ARWR) is 29.64

What is the Market Cap of Arrowhead Pharmaceuticals Inc?

The market capitalization of Arrowhead Pharmaceuticals Inc (ARWR) is $1.69B

What is Arrowhead Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Arrowhead Pharmaceuticals Inc is ARWR

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top